Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication November 20, 2008
- Accepted for publication May 28, 2009
- Published online August 27, 2009.
Article Versions
- previous version (August 18, 2009 - 05:49).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2009 by Society of Nuclear Medicine
Author Information
- Tove Olafsen 1 ,
- David Betting 2 ,
- Vania E. Kenanova 1 ,
- Felix B. Salazar 1 ,
- Pat Clarke 3 ,
- Jonathan Said 4 ,
- Andrew A. Raubitschek 3 ,
- John M. Timmerman 2 and
- Anna M. Wu 1
- 1Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California; 2Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California; 3Department of Radioimmunotherapy, City of Hope National Medical Center, Duarte, California; and 4Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
- For correspondence or reprints contact: Tove Olafsen, UCLA Crump Institute for Molecular Imaging, California NanoSystems Institute, 570 Westwood Plaza, Building 114, Box 951770, Los Angeles, CA 90095-1770. E-mail: tolafsen{at}mednet.ucla.edu
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab')2 Fragments of Obinutuzumab in Lymphoma
- A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues
- The Immunoimaging Toolbox
- Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
- ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo
- Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma
- Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers
- First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
- Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging
- Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET
- Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo
- Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP
- A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma
- Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
- Expression of Antibody Fragments with a Controlled N-Glycosylation Pattern and Induction of Endoplasmic Reticulum-Derived Vesicles in Seeds of Arabidopsis
- Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma